140 related articles for article (PubMed ID: 28419541)
1. When should active surveillance for prostate cancer stop if no progression is detected?
de Carvalho TM; Heijnsdijk EAM; de Koning HJ
Prostate; 2017 Jun; 77(9):962-969. PubMed ID: 28419541
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
3. Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men.
de Carvalho TM; Heijnsdijk EA; de Koning HJ
Int J Cancer; 2016 May; 138(10):2522-8. PubMed ID: 26695380
[TBL] [Abstract][Full Text] [Related]
4. Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study.
de Carvalho TM; Heijnsdijk EA; de Koning HJ
BJU Int; 2017 Apr; 119(4):560-566. PubMed ID: 27222299
[TBL] [Abstract][Full Text] [Related]
5. Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.
Mühlberger N; Boskovic K; Krahn MD; Bremner KE; Oberaigner W; Klocker H; Horninger W; Sroczynski G; Siebert U
BMC Public Health; 2017 Jun; 17(1):596. PubMed ID: 28651567
[TBL] [Abstract][Full Text] [Related]
6. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
[TBL] [Abstract][Full Text] [Related]
7. Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
Bokhorst LP; Roobol MJ; Bangma CH; van Leenders GJ
Prostate; 2017 Jul; 77(10):1137-1143. PubMed ID: 28543353
[TBL] [Abstract][Full Text] [Related]
8. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
9. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
10. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
[TBL] [
